Jpmorgan Chase & CO Cognition Therapeutics Inc Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 69 shares of CGTX stock, worth $121. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69
Previous 75
8.0%
Holding current value
$121
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CGTX
# of Institutions
57Shares Held
13.6MCall Options Held
0Put Options Held
0-
Bios Capital Management, LP Fort Worth, TX6MShares$10.6 Million2.56% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ2.21MShares$3.88 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.3MShares$2.3 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA702KShares$1.24 Million0.0% of portfolio
-
Chescapmanager LLC Baltimore, MD503KShares$885,7350.02% of portfolio
About COGNITION THERAPEUTICS INC
- Ticker CGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,710,700
- Market Cap $40M
- Description
- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...